RSCM
JANX icon

Rock Springs Capital Management’s Janux Therapeutics JANX Stock Holding History

Rock Springs Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.1M Buy
367,009
+8,211
+2% +$113K 0.3% 65
2025
Q4 		$4.95M Buy
358,798
+148,432
+71% +$3.49M 0.25% 67
2025
Q3 		$5.14M Buy
210,366
+100
+0% +$2.44K 0.3% 64
2025
Q2 		$4.86M Buy
210,266
+5,800
+3% +$153K 0.3% 65
2025
Q1 		$5.52M Hold
204,466
– – 0.32% 61
2024
Q4 		$10.9M Buy
+204,466
New +$10.8M 0.42% 59

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rock Springs Capital Management's JANX Position: Q1 2026 in Review

Rock Springs Capital Management increased its Janux Therapeutics (JANX) stake by 2.3% in Q1 2026, buying an estimated $113K and bringing the position to 367,009 shares worth $5.1M. The position accounts for 0.3% of the portfolio, ranked #65.

Rock Springs Capital Management first reported a position in JANX in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.9M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Rock Springs Capital Management held 367,009 shares of Janux Therapeutics worth $5.1M as of Q1 2026.
  • Rock Springs Capital Management bought 8,211 Janux Therapeutics shares in Q1 2026, an estimated $113K.
  • Janux Therapeutics made up 0.3% of Rock Springs Capital Management's portfolio in Q1 2026, its #65 holding.
  • Rock Springs Capital Management first reported a position in Janux Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Rock Springs Capital Management's Janux Therapeutics position peaked at $10.9M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.